Oncotelic Therapeutics, Inc.

OTLC ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2009
Operating Activities
Net Income $-24.7M
Depreciation & Amortization
Depreciation $123.0K
Amortization
Stock-Based Compensation $530.0K
Net Cash from Operating Activities $-28.7M
Investing Activities
Capital Expenditures $109.0K
Business Acquisitions
Net Cash from Investing Activities $2.9M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $21.4M
Net Change in Cash $-4.3M
Free Cash Flow $-28.8M
← Newer Page 3 of 3 Older →